Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Authors:	Keystone Edward Heijde Désireé van der Mason David Landewé Robert Vollenhoven Ronald Van Combe Bernard Emery Paul Strand Vibeke Mease Philip Desai Chintu Pavelka Karel

Affiliation:	University of Toronto, Toronto, Ontario, Canada. edkeystone@mtsinai.on.ca

Abstract:

Keywords:
本文献已被 PubMed 等数据库收录！